Pharmacogenetic effects of single nucleotide polymorphisms commonly associated with antiretroviral therapy metabolism

Author:

Bazhenova A.1ORCID,Mironov K.1ORCID,Kravchenko A.1ORCID,Akimkin V.1ORCID

Affiliation:

1. Central Research Institute of Epidemiology

Abstract

Introduction. Identification of pharmacogenetic effects on antiretroviral therapy (ART) has become an important milestone to reach in the advancement of personalised treatment for HIV-positive patients. The therapy schemes are accompanied by multiple side effects. Therapy effectiveness and adverse reactions can be dictated by individual genetic predisposition factors, which should be taken into account for an optimal prescription. Some genetic markers (HLA-B*57:01 and UGT1A1*28), were already proven to improve discontinuation rates, and efforts are allocated to expand the range of clinically-relevant genetic tests.Objective. In this review, an updated summary of genetic polymorphisms and their effects defining patients’ tolerability to ART is presented. The aim of this research is to assess single nucleotide polymorphisms (SNPs) present in the genes that encode proteins involved in ART metabolism and transport. This review will be used to develop a PCR-based testing methodology for the detection and confirmation of risk alleles in the Caucasian population.Materials and methods. Data from 46 original research papers and reviews was analysed. Allele frequencies of the most relevant polymorphisms were checked against the data for European population.Results. As an outcome of this review, a few most promising SNPs were selected for future research. Firstly, ABCC4 rs1751034 and rs3742106 and ABCC10 rs9349256 and rs2125739 were associated with an increased risk of renal impairment, higher plasma concentration, and toxicity when treated with tenofovir. Parallel analysis of ABCC4 and ABCC10 SNP effects on renal impairment together with CYP24A1 rs2248359 that was recently reported as a potential renal toxicity marker might be more informative. Secondly, CYP2B6 rs3745274 that was associated with an increased efavirenz plasma concentration, and increased risk of liver and CNS toxicity should be evaluated. SNPs in CYP2B6, CYP2A6 (rs28399433), and CYP3A4 (rs4646437) should be evaluated in parallel since possession of all three variants might put patients at a much higher risk.Conclusion. Identified alleles could become new markers used in drug prescription protocols if significant effect in Caucasian population will be found. The most relevant SNPs should be tested in in supporting future studies to evaluate the significance for patients with HIV in Russia.

Publisher

Baltic Medical Education Center

Subject

Infectious Diseases,Public Health, Environmental and Occupational Health,Immunology

Reference46 articles.

1. Ryom L., Cotter A., De Miguel R., Béguelin C., Podlekareva D., Arribas J.R., Marzolini C., Mallon Pgm., Rauch A., Kirk O., Molina J.M., Guaraldi G., Winston A., Bhagani S., Cinque P., Kowalska J.D., Collins S., Battegay M., EACS Governing Board. 2019 update of the European AIDS Clinical Society Guidelines for treatment of people living with HIV version 10.0 // HIV Medicine. 2020. Vol. 21, No. 10. P. 617–624. doi: 10.1111/hiv.12878.

2. Sousa-Pinto B., Pinto-Ramos J., Correia C., Gonçalves-Costa G., Gomes L., Gil-Mata S., Araújo L., Delgado L. Pharmacogenetics of abacavir hypersensitivity: A systematic review and meta-analysis of the association with HLA-B*57:01 // Journal of Allergy and Clinical Immunology. 2015. Vol. 136, No. 4. P. 1092–1094.e3. doi: 10.1016/j.jaci.2015.03.019.

3. Mounzer K., Hsu R., Fusco J.S., Brunet L., Henegar C.E., Vannappagari V., Stainsby C.M., Shaefer M.S., Ragone L., Fusco G.P. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study // AIDS Research and Therapy. 2019. Vol. 16, No. 1. doi: 10.1186/s12981-019-0217-3.

4. Sanchez-Giron F., Carnevale A. In Mexican Mestizos the HCP5 rs2395029 SNP may be a genetic marker for screening abacavir hypersensitivity // Pharmacogenomics. 2012. Vol. 13, No. 3. P. 251–252. doi: 10.2217/pgs.11.169

5. Zubiaur P., Saiz-Rodríguez M., Villapalos-García G., Navares-Gómez M., Koller D., Abad-Santos F. HCP5 rs2395029 is a rapid and inexpensive alternative to HLA-B*57 // Pharmacogenetics and Genomics. 2020. Publish Ahead of Print. doi: 10.1097/fpc.0000000000000421.

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3